Natural Psychedelics Extraction & Standardization Obtains Two New US Patents

Natural Psychedelics Extraction & Standardization Obtains Two New US Patents

Clinical-stage psychedelics drug development company Filament Health Corp. FLHLF has obtained two new patents for the extraction and standardization of natural psilocybin and associated psychedelic compounds by the USPTO. 

Filament’s proprietary technology to extract and standardize stable doses of natural compounds from magic mushrooms received the first-ever patent on August 3, 2021, and built on other three patents by the USPTO and five by the Canadian IP Office.

The two new patents, which describe technology for transforming variable psychedelic raw materials into pharmaceutical-grade drug candidates, add to the company’s IP portfolio which now consists of ten patents for extracting and standardizing methods of natural psychedelics.

Filament’s IP director Taran Grey said that when the company was founded it was thought that producing stable psilocin was impossible.

“We have since been granted patent protection for successful production of psilocin at all stages of manufacture: from extraction to purification to standardization and beyond,” Grey stated, exemplifying with Filament’s issued patents around noningestive administration.

“The fact that we have never had a patent application denied, compared to the industry average of a less than 50% success rate, is further validation of this talent," he said.

Photo courtesy of Susie Hedberg and only_kim on Shutterstock.

Posted In: Economics of Psychedelics InvestingPsilocybinUSPTOCannabisNewsPenny StocksPsychedelicsLegalManagementMarkets


Meet the biggest cannabis industry players and make deals that will push the industry forward.

Featuring live company presentations, insider panels, and unmatched access to networking, the Benzinga Cannabis Capital Conference is where cannabis executives and entrepreneurs meet.

Join us April 11-12, 2023 at Fontainebleau Miami Beach in sunny Florida.